Ask AI
ProCE Banner Activity

What You Need to Know About Managing Anemia in Patients With Lower-risk MDS in 2025

Clinical Thought

Get up-to-date on the management of anemia with LR-MDS in this commentary with expert responses to questions from healthcare professionals at a recent live webinar. 

Released: July 25, 2025

Expiration: January 24, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Bristol Myers Squibb and Geron.

Bristol Myers Squibb

Geron

Disclosure

Primary Author

Rami Komrokji, MD: consultant/advisor/speaker: Bristol Myers Squibb, Daiichi Sankyo, Geron, Jazz, PharmaEssentia, Rigel, Sevier, Sobi, Sumitomo; researcher: Keros.

Maximilian Stahl, MD: consultant/advisor/speaker: Bristol Myers Squibb, GlaxoSmithKline, Kura, Kymera, Novartis, Rigel, Sierra Oncology, Sobi, Syndax; medical safety monitoring board: Keros.

Amer Zeidan, MBBS, MHS: consultant/advisor/speaker/clinical trial committee: AbbVie, Akeso, Agios, Amgen, Astellas, BeiGene, BioCryst, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Chiesi/Cornerstone Biopharma, Daiichi Sankyo, Dr Reddy, Epizyme, FibroGen, Glycomimetics, Genentech, Gilead, Geron, GSK, Janssen, Jasper, Karyopharm, Keros, Kura, Kyowa Kirin, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrodinger, Seattle Genetics, Servier, Shattuck Labs, Syndax, Syros, Takeda, Treadwell, Taiho, Vincerx, Zentalis.